These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys. Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S J Virol; 2017 May; 91(10):. PubMed ID: 28250127 [TBL] [Abstract][Full Text] [Related]
12. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice. Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113 [TBL] [Abstract][Full Text] [Related]
13. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231 [TBL] [Abstract][Full Text] [Related]
14. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425 [TBL] [Abstract][Full Text] [Related]
15. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates. Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239 [TBL] [Abstract][Full Text] [Related]
16. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. Herbert AS; Kuehne AI; Barth JF; Ortiz RA; Nichols DK; Zak SE; Stonier SW; Muhammad MA; Bakken RR; Prugar LI; Olinger GG; Groebner JL; Lee JS; Pratt WD; Custer M; Kamrud KI; Smith JF; Hart MK; Dye JM J Virol; 2013 May; 87(9):4952-64. PubMed ID: 23408633 [TBL] [Abstract][Full Text] [Related]
17. Evaluation in nonhuman primates of vaccines against Ebola virus. Geisbert TW; Pushko P; Anderson K; Smith J; Davis KJ; Jahrling PB Emerg Infect Dis; 2002 May; 8(5):503-7. PubMed ID: 11996686 [TBL] [Abstract][Full Text] [Related]
18. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779 [TBL] [Abstract][Full Text] [Related]
19. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. Ewer K; Rampling T; Venkatraman N; Bowyer G; Wright D; Lambe T; Imoukhuede EB; Payne R; Fehling SK; Strecker T; Biedenkopf N; Krähling V; Tully CM; Edwards NJ; Bentley EM; Samuel D; Labbé G; Jin J; Gibani M; Minhinnick A; Wilkie M; Poulton I; Lella N; Roberts R; Hartnell F; Bliss C; Sierra-Davidson K; Powlson J; Berrie E; Tedder R; Roman F; De Ryck I; Nicosia A; Sullivan NJ; Stanley DA; Mbaya OT; Ledgerwood JE; Schwartz RM; Siani L; Colloca S; Folgori A; Di Marco S; Cortese R; Wright E; Becker S; Graham BS; Koup RA; Levine MM; Volkmann A; Chaplin P; Pollard AJ; Draper SJ; Ballou WR; Lawrie A; Gilbert SC; Hill AV N Engl J Med; 2016 Apr; 374(17):1635-46. PubMed ID: 25629663 [TBL] [Abstract][Full Text] [Related]